Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million

Reuters

2025/11/06

<a href="https://laohu8.com/S/VMD">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million

Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581707336"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581707336\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581707336?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581707336","market":"nz","top_or_hot":-1,"title":"Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VMD\">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-06 05:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VMD\">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VMD","symbol_name":"Viemed Healthcare, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3t00dX:1","article_id":"2581707336","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581707336","pubTimestamp":1762378433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VMD":"Viemed Healthcare, Inc.","BK4196":"保健护理服务"},"translate_title":"Viemed Healthcare报告第三季度净收入为7190万美元，净利润为350万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VMD":0.9},"content_text":"Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    \n\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}